Rockwell Medical (RMTI) risk factors, FY2025 10-K

Rockwell Medical's FY2025 10-K, filed Mar 26, 2026, lists 33 risk factors in 4 groups. Against the prior year's 32: 3 new, 2 dropped, 9 substantially reworded.

Open RMTI in Gloom →
Rockwell Medical's chart, financials and news, free in your browser.Open RMTI in Gloom →
Risk factors listed
334 groups
New this year
3vs 32 last year
Dropped
2since the prior 10-K
Substantially reworded
9of those kept
Section length
11k wordsItem 1A

What the changes say

  • Loss of our largest customer who represented nearly half of our sales volume forced major operational restructuring and plant closure.

What changed since the prior 10-K

New

  • NewRISKS RELATED TO OUR BUSINESS

    Advancements in treatment modalities for end stage kidney disease and the introduction of new pharmacologic therapies may reduce demand for our hemodialysis concentrate products

    Technological advancements and new pharmacologic therapies for end stage kidney disease could reduce demand for our hemodialysis concentrate products.

  • NewRISKS RELATED TO OUR FINANCIAL POSITION

    The reduction in sales to our largest customer required us to right size our operations and our inability to appropriately reduce our scale would have a negative impact on our results of operations and financial condition

    Our largest customer moved a substantial portion of its business to another supplier in 2025, forcing us to close our South Carolina facility and cut costs.

  • NewRISKS RELATED TO LEGAL AND REGULATORY

    successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and day-to-day business operations

    We may face costly intellectual property claims from former employers of our employees or directors.

Dropped

  • DroppedRISKS RELATED TO OUR FINANCIAL POSITION

    The loss of our largest customer will negatively impact our revenue, and we may not be able to replace that lost revenue with new business

    Loss of our largest customer will negatively impact revenue by $34 million.

  • DroppedRISKS RELATED TO OUR BUSINESS

    We have in-licensed rights to certain patents that cover Triferic. If we fail to remain in compliance with these license agreements, we could forfeit the rights to these patents, which could result in our noncompliance with those partnership agreements

Reworded

  • 75% rewrittenRISKS RELATED TO OUR BUSINESS

    A small group of customers account for a substantial portion of the end user sales of our concentrate products. The loss of any of these customers could materially and adversely affect our business, results of operations, financial position and cash flows

    Updated to reflect that our largest customer reduced its business with us in 2025 rather than just notifying us of the impending change.

    Was: A few customers account for a substantial portion of the end user sales of our concentrate products. The loss of any of these customers could materially and adversely affect our business, results of operations, financial position and cash flows

  • 46% rewrittenRISKS RELATED TO OUR FINANCIAL POSITION

    Our financial projections are based on various assumptions that may not come to fruition

    Added selective automation of operations as an assumption underlying our financial projections.

    Was: Our revenue growth and profitability projections are based on various assumptions that may not come to fruition

  • 43% rewrittenRISKS RELATED TO OUR BUSINESS

    We have been, and may continue to be, materially and adversely affected by increases in raw material, labor and transportation costs and may be unable to recover certain costs due to provisions in our contracts that limit price increases, and we may lose other customers due to price sensitivity

    Clarified that we have no control over raw material and transportation prices.

  • 35% rewrittenRISKS RELATED TO OUR BUSINESS

    Certain aspects of our production and other processes are manual, which introduces risk of error and may result in rising production costs

    Added that customer unwillingness to pay higher prices for manual production costs could lead to lost customers.

    Was: Our production and other processes are somewhat manual, which introduces risk of error and may result in rising production costs

  • 32% rewrittenRISKS RELATED TO LEGAL AND REGULATORY

    Our products may have or have had undesirable side effects, and our product liability insurance may not be sufficient to protect us from material liability or harm to our business

    Minor phrasing updates regarding potential side effects from hemodialysis concentrates and discontinued Triferic.

  • 30% rewrittenRISKS RELATED TO OUR BUSINESS

    We expect that if we continue to be subject to the limitations on price increases in our contracts, increasing costs and decreasing volumes may continue to negatively impact our profit margins and materially and adversely affect our financial position and results of operations

    Added surcharges and other methods to the ways we attempt to pass cost increases along to customers.

    Was: We expect that if we continue to be subject to the limitations on price increases in our contracts, increasing costs and decreasing volumes may continue to negatively impact our profit margins and materially and adversely affect our financial position

  • 29% rewrittenRISKS RELATED TO OUR BUSINESS

    Market dynamics in the concentrates business have resulted in fluctuating volumes that could lead to the implementation of cost-saving measures that would have a material and adverse effect on our business

    Expanded customer cost-saving measures to include switching to single-use bicarbonate bags in addition to canisters.

    Was: Market dynamics in our concentrates business have resulted in fluctuating volumes that could lead to the implementation of cost-saving measures that would have a material and adverse effect on our business

  • 27% rewrittenRISKS RELATED TO OUR FINANCIAL POSITION

    We have limited capital resources and will likely need additional funding to expand our business. If we are unable to raise additional capital on attractive terms, or at all, we may be unable to sustain our operations

    Updated financial figures for the period ending December 31, 2025, including a cumulative deficit of $403.0 million and working capital of $28.6 million.

    Was: We have limited capital resources and will likely need additional funding to operate and expand our business. If we are unable to raise additional capital on attractive terms, or at all, we may be unable to sustain our operations

  • 21% rewrittenRISKS RELATED TO OUR COMMON STOCK

    We may fail to qualify for continued listing on Nasdaq, which could make it more difficult for our stockholders to sell their shares

All 33 risk factors

Headings as the filing states them, in filing order.

RISKS RELATED TO OUR BUSINESS

  1. 01We face competition in the concentrates market and have large competitors with substantial resources
  2. 02A small group of customers account for a substantial portion of the end user sales of our concentrate products. The loss of any of these customers could materially and adversely affect our business, results of operations, financial position and cash flows75% rewritten
  3. 03Advancements in treatment modalities for end stage kidney disease and the introduction of new pharmacologic therapies may reduce demand for our hemodialysis concentrate productsNew
  4. 04If our customers move back to entering into long-term bundled product contracts with suppliers, our business could suffer
  5. 05We have been, and may continue to be, materially and adversely affected by increases in raw material, labor and transportation costs and may be unable to recover certain costs due to provisions in our contracts that limit price increases, and we may lose other customers due to price sensitivity43% rewritten
  6. 06We expect that if we continue to be subject to the limitations on price increases in our contracts, increasing costs and decreasing volumes may continue to negatively impact our profit margins and materially and adversely affect our financial position and results of operations30% rewritten
  7. 07Unfavorable weather, economic conditions or supply shortages could materially and adversely affect our business, financial condition or results of operations
  8. 08Certain aspects of our production and other processes are manual, which introduces risk of error and may result in rising production costs35% rewritten
  9. 09We may not be successful in expanding our business or in our business development efforts related to in-licensing, acquisitions or other business collaborations. Even if we are able to enter into business development arrangements, they could have a negative impact on our business and our profitability
  10. 10Our business depends on government funding of health care, and changes could impact our ability to be paid in full for our products, increase prices or cause consolidation in the dialysis provider market
  11. 11Our medical device products are life-sustaining and any failure to supply them to our customers could result in scrutiny and negatively impact our reputation and stock price
  12. 12Market dynamics in the concentrates business have resulted in fluctuating volumes that could lead to the implementation of cost-saving measures that would have a material and adverse effect on our business29% rewritten
  13. 13Our business and operations would suffer in the event of a security breach, system failure, invasion, corruption, destruction or interruption of our or our business partners’ critical information technology systems or infrastructure
  14. 14Our future success depends on our ability to retain executives and key employees and to attract, retain and motivate qualified personnel in the future
  15. 15We use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly

RISKS RELATED TO OUR FINANCIAL POSITION

  1. 16The reduction in sales to our largest customer required us to right size our operations and our inability to appropriately reduce our scale would have a negative impact on our results of operations and financial conditionNew
  2. 17We have limited capital resources and will likely need additional funding to expand our business. If we are unable to raise additional capital on attractive terms, or at all, we may be unable to sustain our operations27% rewritten
  3. 18Our existing capital resources may not be adequate to finance our operating cash requirements in the future and additional capital that we may need to operate or expand our business may not be available
  4. 19Our financial projections are based on various assumptions that may not come to fruition46% rewritten

RISKS RELATED TO LEGAL AND REGULATORY

  1. 20Our business is highly regulated, resulting in additional expense and risk of noncompliance that can materially and adversely affect our business, results of operations, financial position and cash flows
  2. 21Our business operations may subject us to numerous commercial disputes, claims, lawsuits and/or investigations
  3. 22We may become the target of litigation, which is costly and time-consuming to defend
  4. 23Our products may have or have had undesirable side effects, and our product liability insurance may not be sufficient to protect us from material liability or harm to our business32% rewritten
  5. 24successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and day-to-day business operationsNew
  6. 25Our business could be impacted as a result of actions by activist stockholders, including as a result of a potential proxy contest for the election of directors at our annual meeting

RISKS RELATED TO OUR COMMON STOCK

  1. 26The market price of our common stock has fluctuated in the past, and is likely to continue to be volatile, which could subject us to litigation
  2. 27We may fail to qualify for continued listing on Nasdaq, which could make it more difficult for our stockholders to sell their shares21% rewritten
  3. 28Shares eligible for future sale may affect the market price of our common stock
  4. 29Our ability to use our net operating loss carryforwards to offset potential taxable income and related income taxes that would otherwise be due may be limited
  5. 30We do not anticipate paying dividends in the foreseeable future
  6. 31If securities analysts do not publish research or reports about our business, or if they publish negative evaluations, the price of our common stock could decline
  7. 32Our certificate of incorporation, bylaws and Delaware law could prevent a third party from acquiring us (even if an acquisition would benefit our stockholders), may limit the ability of our stockholders to replace our management and limit the price that investors might be willing to pay for shares of our common stock
  8. 33We are not subject to the provisions of Section 203 of the Delaware General Corporation Law, which could negatively affect your investment

Other Rockwell Medical 10-Ks

  • FY2024 10-K risk factors
    32 risks

    Rockwell Medical faces severe customer concentration with its largest customer leaving by mid-2025. The company has limited capital resources with a cumulative deficit of $397.7 million. Operations depend heavily on manual production processes and government healthcare funding.

    Filed Mar 20, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.